Trial Profile

A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC [chronic hepatitis C] Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough

04 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
04 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
23 Jun 2010 Planned end date changed from Jun 2010 to Dec 2010 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com